There are no adequate and well-controlled studies of VEVYE (cyclosporine ophthalmic solution) 0.1% administration in pregnant women to inform a drug-associated risk. Oral administration of cyclosporine to pregnant rats or rabbits did not produce teratogenicity at clinically relevant doses. VEVYE doses are approximately 4,700 times lower than recommended oral doses, with blood concentrations being undetectable after topical administration.

Please see more information regarding VEVYE use in specific information in the Full Prescribing Information.